This federal Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) provides $249,732 in funding to Virginia Commonwealth University (VCU) for research on novel kappa opioid receptor (KOR) agonists and their potential to promote central nervous system (CNS) repair. The award, which runs from September 1, 2024 to August 31, 2025, will enable VCU to conduct research aimed at developing effective treatments for CNS-related conditions relevant to military personnel and the broader public. As a prominent research university with extensive federal funding experience, VCU is well-positioned to execute this biomedical research project and deliver meaningful outcomes aligned with the priorities of the DHA and the broader Military Medical Research and Development program.